- Home
- EDF vs ELTX Comparison
EDF vs ELTX Comparison
Compare EDF & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- ELTX
- Stock Information
- Founded
- EDF 2010
- ELTX 2011
- Country
- EDF United States
- ELTX United States
- Employees
- EDF N/A
- ELTX N/A
- Industry
- EDF Investment Managers
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- ELTX Health Care
- Exchange
- EDF Nasdaq
- ELTX Nasdaq
- Market Cap
- EDF 154.9M
- ELTX 158.5M
- IPO Year
- EDF N/A
- ELTX N/A
- Fundamental
- Price
- EDF $4.91
- ELTX $8.67
- Analyst Decision
- EDF
- ELTX Strong Buy
- Analyst Count
- EDF 0
- ELTX 1
- Target Price
- EDF N/A
- ELTX $13.00
- AVG Volume (30 Days)
- EDF 160.6K
- ELTX 101.9K
- Earning Date
- EDF 01-01-0001
- ELTX 11-13-2025
- Dividend Yield
- EDF 13.14%
- ELTX N/A
- EPS Growth
- EDF N/A
- ELTX N/A
- EPS
- EDF N/A
- ELTX N/A
- Revenue
- EDF N/A
- ELTX N/A
- Revenue This Year
- EDF N/A
- ELTX N/A
- Revenue Next Year
- EDF N/A
- ELTX N/A
- P/E Ratio
- EDF N/A
- ELTX N/A
- Revenue Growth
- EDF N/A
- ELTX N/A
- 52 Week Low
- EDF $3.51
- ELTX $4.60
- 52 Week High
- EDF $5.50
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- EDF 41.93
- ELTX 33.13
- Support Level
- EDF $4.89
- ELTX $8.60
- Resistance Level
- EDF $5.03
- ELTX $9.49
- Average True Range (ATR)
- EDF 0.06
- ELTX 0.47
- MACD
- EDF -0.00
- ELTX 0.01
- Stochastic Oscillator
- EDF 13.79
- ELTX 9.92
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.